Clinical Trials
21 trialsNCT02993523 2026-05-15
Viale-a
AbbVie
Phase 3 Completed
NCT04102020 2026-04-08
VIALE-M
AbbVie
Phase 3 Completed
NCT04266301 2026-01-13
STIMULUS-MDS2
Novartis
Phase 3 Terminated
NCT02421939 2025-12-04
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Inc
Phase 3 Completed
NCT03173248 2025-11-10
AGILE
Servier
Phase 3 Active not recruiting
NCT03268954 2025-10-29
PANTHER
Takeda
Phase 3 Completed
NCT02752035 2025-09-12
A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
Astellas Pharma Inc
Phase 3 Completed
NCT01757535 2025-07-08
QUAZAR AML-001
Celgene
Phase 3 Completed
NCT02577406 2025-05-18
IDHENTIFY
Celgene
Phase 3 Completed
NCT05079230 2025-04-04
ENHANCE-3
Gilead Sciences
Phase 3 Terminated
NCT03745716 2025-03-18
APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
Aprea Therapeutics
Phase 3 Completed
NCT04778397 2025-02-05
ENHANCE-2
Gilead Sciences
Phase 3 Terminated
NCT03703375 2024-07-08
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
Celgene
Phase 3 Active not recruiting
NCT04842604 2023-12-18
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
Pfizer
Phase 3 Completed
NCT03416179 2023-04-21
BRIGHT AML1019
Pfizer
Phase 3 Completed
NCT03941964 2023-03-20
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
AbbVie
Phase 3 Completed
NCT03151408 2022-03-10
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Helsinn Healthcare SA
Phase 3 Terminated
NCT02951156 2020-12-17
Javelin DLBCL
Pfizer
Phase 3 Terminated
NCT00887068 2020-01-14
Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)
M.D. Anderson Cancer Center
Phase 3 Completed
NCT02785900 2018-12-12
CASCADE
Seagen Inc.
Phase 3 Terminated
NCT01074047 2017-08-29
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
Celgene
Phase 3 Completed